Hologic, Inc. (HOLX)
| Market Cap | 16.71B |
| Revenue (ttm) | 4.10B |
| Net Income (ttm) | 565.70M |
| Shares Out | 222.91M |
| EPS (ttm) | 2.49 |
| PE Ratio | 30.11 |
| Forward PE | 16.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,728,608 |
| Open | 75.00 |
| Previous Close | 74.86 |
| Day's Range | 74.82 - 75.10 |
| 52-Week Range | 51.90 - 80.31 |
| Beta | 0.70 |
| Analysts | Hold |
| Price Target | 79.64 (+6.23%) |
| Earnings Date | Nov 3, 2025 |
About HOLX
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos... [Read more]
Financial Performance
In 2025, Hologic's revenue was $4.10 billion, an increase of 1.74% compared to the previous year's $4.03 billion. Earnings were $565.70 million, a decrease of -28.35%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for HOLX stock is "Hold." The 12-month stock price target is $79.64, which is an increase of 6.23% from the latest price.
News
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test.
New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA.
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking.
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025.
Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Holog...
Blackstone, TPG to Buy Hologic for Up to $18.3 Billion
Under the terms of the deal, Blackstone and TPG agreed to acquire all outstanding shares of the women's-health company for $76 apiece in cash.
Blackstone, TPG to acquire medical device maker Hologic in up to $18.3 billion deal
Blackstone and TPG have agreed to acquire medical diagnostics firm Hologic in an up to $18.3 billion deal, the company said on Tuesday.
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share
MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)---- $HOLX #aquisition--Hologic to be Acquired by Blackstone and TPG for up to $79 per Share.
Hologic Stock Rises as Report Says Blackstone and TPG in Advanced Takeover Talks
The maker of women's health products rejected a $16 billion offer from the parties in May.
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025.
Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #Bacterial--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fus...
New Survey Results Underscore the Need to #BustTheMyth About Mammograms
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #BCAM--New Survey Results Underscore the Need to #BustTheMyth About Mammograms.
Volition Signs Co-Marketing and Services Agreement with Hologic
HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Holog...
Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm
HAUPPAUGE, N.Y. , Sept. 29, 2025 /PRNewswire/ -- Minicarm.com, a leading provider of imaging solutions for orthopedic and surgical practices, is proud to announce that it has secured an allocation of ...
New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI.
Blackstone and TPG revive interest in buying Hologic, source says
Private equity firms Blackstone and TPG revived their interest in acquiring medical device maker Hologic , a person close to the transaction said on Wednesday.
Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Hologic, Inc. (NASDAQ:HOLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Stephen MacMillan - Chairman, CEO & President Conference Call P...
Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference.
Hologic (HOLX) Q3 Revenue Beats 1%
Hologic (HOLX) Q3 Revenue Beats 1%
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.
Hologic raises annual profit forecast on diagnostic and surgical demand
Medical equipment maker Hologic on Wednesday raised its annual profit forecast, anticipating strong demand for its molecular diagnostic devices and surgical products.
Hologic Announces Financial Results for Third Quarter of Fiscal 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2025.
Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu s...
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025.
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.